Atossa Genetics announced their Q3 earnings today, along with an update on their ForeCYTE Breast Health Test recall and plans for product launches and relaunches in 2014. Net loss for the quarter ended September 30, 2013, was $3.5 million, or $0.22 per share, compared with net loss of $1.1 million, or $0.10 per share, for […]
I do not get annual mammograms, even though I am 42. I got a baseline in my late 30s in preparation for regular mammograms in a few years. That was before the U.S. Preventive Services Task Force revised its recommendations about the benefits of mammograms for women my age. The more I read about overdiagnosis […]
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
There is a new screening for breast cancer that could have allowed Angelina Jolie to choose watchful waiting instead of a double mastectomy. Earlier this year, Atossa Genetics launched the ForeCYTE Breast Health Test. The test uses a device similar to a manual breast pump and cytopathology to study the cells that line the milk […]